Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce that the Center for Drug Evaluation of the National Medical Products Administration of China granted Breakthrough Therapy Designations for BRII-877 (tobevibart), a broadly neutralizing monoclonal antibody targeting hepatitis B virus ("**HBV**"), and BRII-835 (elebsiran), an investigational HBV-targeting small interfering ribonucleic acid, today. This represents another milestone in the Company's pursuit of a functional cure for HBV, following the Breakthrough Therapy Designation granted for BRII-179, a recombinant protein-based HBV immunotherapeutic, in November 2023.

The Breakthrough Therapy Designation for BRII-877 (tobevibart) was supported by Phase 1 and 2 studies conducted by Vir Biotechnology, Inc. ("**Vir**") and the Company. By the end of September 2023, more than 350 people living with HBV have received treatment of BRII-877 (tobevibart). Data have shown BRII-877 (tobevibart) to be well-tolerated and to have resulted in marked decreases in hepatitis B surface antigen levels suggesting the potential for BRII-877 (tobevibart) to be an important part of a treatment regimen for people living with chronic HBV infection and hepatitis D virus ("**HDV**") infection. The Breakthrough Therapy Designation for BRII-835 (elebsiran) was supported by Phase 1 and 2 studies conducted by the Company and its partner Vir. By the end of September 2023, more than 570 people living with HBV have participated in clinical studies where BRII-835 (elebsiran) has been shown to be well-tolerated and has demonstrated direct antiviral activity against HBV in participants with chronic HBV and HDV infection.

"Receiving Breakthrough Therapy Designations for BRII-835 and BRII-877 as well as the earlier Breakthrough Therapy Designation for BRII-179 further support our long-held scientific rationales in the development of functional cure combination regimens for patients with chronic HBV infection," said Dr. Qing Zhu, the Head of China Research and Development of the Company. "The Company and our partner Vir have conducted numerous clinical trials over the past five years, from which we have gained comprehensive clinical safety and efficacy data as well as critical insight towards our late-stage development plan and achieving potentially higher rates of HBV functional cure in broader patient populations."

Having three breakthrough therapeutic modalities puts the Company in a unique position to address the broader populations of HBV infections including co-infection with HDV. As part of the Company's approach to developing a functional cure for HBV, the Company and its partner Vir are progressing plans to initiate multiple combination studies in 2024 to further optimize the curative regimens that will inform the Company's registration strategy to bring the best regimens to HBV patients.

Cautionary Statement: There is no assurance that BRII-179, BRII-835 or BRII-877 will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, May 14, 2024

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.